5 Literaturverzeichnis

Adkins JC et al.: Edrecolomab (monoclonal antibody 17-1A), Drugs 1998, 56(4):619-28


Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L: Phase II study of

Comment in: J Clin Oncol. 1996 Mar; 14(3):697-9


Blanar MA, Boettger EC, Flavell RA: Transcriptional activation of HLA-DR alpha by interferon gamma requires a trans-acting protein, Proc Natl Acad Sci USA 1988, Jul; 85(13):4672-6


Boon T; van der Bruggen P: Human tumor antigens recognized by T lymphocytes, J Exp Med 1996; 183:725-729

Boon T; Coulie PG; Van den Eynde B: Tumor antigens recognized by T cells, Immunology Today 1997; 18(6):267-268


Brossart P et al.: Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes, Cancer Res 1998; 58(4):732-736


Cabrera T et al.: High frequency of antered HLA class I phenotypes in invasive breast carcinomas, Hum Immunol 1996; 50(2):127-34


Clynes RA et al.: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets, Nature Medicine 2000; 6(4):443-446


Dakappagari NK et al.: Prevention of mammary tumours with a chimeric HER-2 B-cell epitope peptide vaccine, Cancer Res 2000; 60:3782-3789


Comment in: J Pathol. 2000; 191(1):102-3


De Vries MJ: Treatment of mouse lymphosarcoma by total body irradiation and by injection of bone marrow and lymph node cells, J Natl Cancer Inst 1958; 21:117


Ding L, Linsley PS, Germain RN, Shevach EM: IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression, J Immunol 1993; 151:1224-34


Disis ML et al.: High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer; J Clin Oncol 1997; 15:3363-3367


Dobrzanski MJ et al.: Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor, J Immunol 2000; 164(2):916-25

Dobrzanski MJ et al.: Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection, J Immunol 2001; 167(1):424-34

Douillard JY et al.: Immunotherapy of gastrointestinal cancer with monoclonal antibodies, Med Oncol Tumor Pharmacother 1986; 3(3-4):141-6


Dunnion DJ et al.: Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro, Immunology 1999; 98(4):541-50
Ehrlich P: Über den jetzigen Stand der Karzinomforschung, Nederlandsch Tijdschrift voor Geneeskunde 1909; Eerste Heft A No.5:273-290


Essermann JL et al.: Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice, Cancer Immunol Immunother 1999; 47:337-342


Feuerer M et al.: Enrichment in memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients, Int J Cancer 2001 a) :92,96-105


Foon KA et al.: Clinical and immune responses in resected colon cancer patients treated with anti-idiotypic monoclonal antibody vaccine that targets the carcinoembryonic antigen, J Clin Oncol 1999; 17(9):2889-2885


Goedegebuure PS, Douville CC, Doherty JM, Linehan DC, Lee KY, Ganguly EK, Eberlein TJ: Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer, Cell Immunol 1997; 175(2):150-6


Grosenbach DW, Barrientos JC, Schlom J, Hodge JW: Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects, Cancer Res 2001; 61:4497-4505


Gure AO, Stockert E, Arden KC, Boyer AD, Viars CS, Scanlan MJ, Old LJ, Chen YT: CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis, Int J Cancer 2000; 85(5):726-32

Hakim AA: Peripheral blood lymphocytes from patients with cancer lack interleukin-2 receptors, Cancer 1988, 61:689-701


Hamann et al.: Phenotypic and functional separation of memory and effector human CD8+ T cells, J Exp Med 1997; 186(9):1407-18


Hom SS et al.: Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared antigens, J Immunother 1993 a); 13(1):18-30

Hom SS et al.: Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: analysis by cytokine secretion, Cancer Immunol Immunother 1993 b); 36:1-8


Ioanides CG et al.: Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene, Cell Immunol 1993; 151(1):225-34


Jerome KR et al.: Cytotoxic t lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells, Cancer Res 1991; 51(11):2908-16

Jiang XP et al.: Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125 results in immune and clinical responses in breast cancer patients, Cancer Biother Radiopharm 2000; 15(5):495-505

Jojovic M et al.: Epithelial glycoprotein-2 expression is subject to regulatory process in epithelial-mesenchymal transitions during metastases: an investigation of human cancers transplanted into severe combined immunodeficient mice, Histochem J 1998; 30(10):723-9

Kageshita T et al.: Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens, Cancer Res 1993; 53(14):3349-54


Karanikas V et al.: High frequency of cytolytic T lymphocytes directed against a Tumor-specific mutated antigen detectable with HLA tetramers in the blood of lung carcinoma patient with long survival, Cancer Res 2001; 61:3718-3724

Kass E et al.: Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with recombinant vaccinia-CEA virus, Cancer Res 1999; 59(3):676-683


Kawakami Y et al.: Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma, J Immunother 2000; 23(1):17-27
Keilholz U et al.: Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients, J Clin Oncol 1998; 16(9):2921-9


Kvale D, Brandtzaeg P: Constitutive and cytokine induced expression of HLA molecules, secretory component, and intercellular adhesion molecule-1 by butyrate in the colonic epithelial cell line HT-29, Gut, 1995, May; 36(5):737-42

Lanzavecchia A; Sallusto F: Dynamics of T lymphocyte Responses: Intermediates, Effectors, and Memory Cells, Science 2000; 290:92-97


Larsen SU et al.: Spontaneous remission in breast cancer, Ugeskr Laeger 1999; 161(26):4001-4

Legha SS et al.: Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy, Semin Oncol 1997; 24;1 Suppl 4:S39-43


Litvinov SV et al.: Epithelial cell adhesion molecule (Ep-Cam) modulates cell-cell interactions mediated by classic cadherins, J Cell Biol 1997, 139(5):1337-48


Mackensen A et al.: Direct evidence to support the immunosurveillance concept in a human regressive melanoma, J Clin Invest 1994; 93(4):1397-402


Maric M, Liu Y: Strong cytotoxic T Lymphocyte responses to a macrophage inflammatory protein 1α-expressing tumor: Linkage between inflammation and specific immunity, Cancer Res 1999; 59:5549-5553


Molto L et al.: Immunologic changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-alpha.2b and IL-2, J Immunother 1999; 22(3):260-7

Momburg F et al.: Selective loss of HLA-A or HLA-B antigen expression in colon carcinoma, J Immunol 1989; 142(1):352-8


Morgan DJ, Kreuwel HT, Sherman LA.: Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens, J Immunol 1999 Jul 15; 163(2):723-7

Mosmann TR, Li L, Sad D: Functions of CD8 T-cell subsets secreting different cytokine patterns, Semin Immunol 1997 a) Apr; 9(2):87-92

Mosmann TR, Li L, Hengartner H, Kagi D, Fu W, Sad S: Differentiation and functions of T cell subsets, Ciba Found Symp 1997 b); 204:148-54


Nagorsen D, Marincola FM: How to analyse ex vivo T-cell responses in cancer patients, In Vivo 2002 a); 16(6):519-25


Pegram MD et al.: Combination of therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity, Semin Oncol 1999; 26(4 Suppl 12):89-95


Piccard M et al.: Closing remarks and treatment guidelines, Eur J Cancer 2001; 37 Suppl 1:30-33


Ras E et al.: Identification of Potential HLA-A *0201 Restricted CTL Epitopes Derived from the Epithelial Cell Adhesions Molecule (Ep-CAM) and the Carcinoembryonic Antigen (CEA), Human Immunology 1997; 53(1):81-89

Reilly RT et al.: HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice, Cancer Res 2000; 60:3569-3576


Renkvist N, Castelli C, Robbins PF, Parmiani G: A listing of human tumor antigens recognized by T cells, Cancer Immunol Immunother 2001; 50:3-15


Rongcun Y et al.: Identification of new HER-2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas, J Immunol 1999; 163(2):1037-44


Rubinfeld B et al.: Stabilization of beta-catenin by genetic defects in melanoma cell lines, Science 1997; 275(5307):1790-2


Sad D, Li L, Mosmann TR: Cytokine-deficient CD8+ Tc1 cells induced by IL-4: retained inflammation and perforin and Fas cytotoxicity but compromised long term killing of tumor cells, J immunol 1997 Jul 15; 159(2):606-13


Scheibenbogen C, Lee KH, Mayer S, Stevanovic S, Moebius U, Herr W, Rammensee HG, Keilholz U: A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients, Clin Cancer Res 1997 a); 3(2):221-6


Schmielau J et al.: Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients, Cancer Res 2001 Jun 15; 61(12):4756-60


Schmittel A, Keilholz U, Thiel E, Scheibenbogen C: Quantification of tumor-specific T lymphocytes with the ELISPOT assay, J Immunother 2000; 23(3):289-95


Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA.: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin), Semin Oncol 1999; 26(4 Suppl 12):60-70


Starzl TE et al.: Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy, Lancet 1984; 1(8377):583-7
Staveley-O'Carroll K et al.: Induction of antigen-specific T cell anergy: an early event in the course of tumor progression, Proc Natl Sci USA 1998; 95(3):1178-83


Tanaka F et al.: Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells, Cancer Res 2000; 60(17):4838-44


Titu LV, Monson JRT, Greenman J: The role of CD8+ T cells in immune responses to colorectal cancer, Cancer Immunol Immunother 2002; 51: 235-247


Trojan A et al.: Generation of cytotoxic T Lymphocytes against native and altered peptides of human leukocyte antigen-A 0201 restricted epitopes from the human epithelial cell adhesion molecule, Cancer Res 2001; 61:4761-4765


Tzankov A et al.: Spontaneous remission in a secondary acute myelogenous leukaemia following invasive pulmonary aspergillosis, Ann Hematol 2001; 80(7):423-5


Van den Eynde; Boon 1997: Tumor antigens recognized by T lymphocytes, International Journal of Clinical + Laboratory Research 1997; 27(2):81-86

van der Bruggen P et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, Science 1991; 254(5038):1643-7


Verdegaal ME et al.: Isolation of broadly reactive tumor-specific, HLA class-I restricted CTL from blood lymphocytes of breast cancer patient, Human Immunology 1999; 60:1195-1206

Vermorken JB et al.: Active specific immunotherapy for stage II and stage III human colon cancer: a randomized trial, Lancet 1999; 353(9150):345-50

Wang RF: Human tumor antigens: implications for cancer vaccine development, Journal of Molecular Medicine 1999 a); 77(9):640-655
Wang RF; Rosenberg SA: Human tumor antigens for cancer vaccine development, Immunologic reviews 1999 b); 170:85-100


Xiang R et al.: Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral vaccine in CEA-transgenic mice, Clin Cancer Res 2001; 7(3 Suppl):856s-864s


Yoshino I, Goedegebuure PS, Peoples GE, Parikh AS, DiMaio JM, Lyerly HK, Gazdar AF, Eberlein TJ: HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer, Cancer Res 1994 b); 54(13):3387-90


Zhong XY et al.: Evaluatin GA733-2 mRNA as a marker for the detection of micrometastatic breast cancer in peripheral blood and bone marrow, Arch Gynecol Obstet 1999; 263;(1-2):2-6